This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

GlaxoSmithKline (GSK) Gets a Sell from Barclays

Tipranks - Tipranks - Thu Jun 18, 5:50AM CDT

Barclays analyst James Gordon CFA maintained a Sell rating on GlaxoSmithKline today and set a price target of £18.00.

Claim 55% Off TipRanks

Gordon CFA covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Galderma Group AG, and AstraZeneca. According to TipRanks, Gordon CFA has an average return of 4.3% and a 50.00% success rate on recommended stocks.

In addition to Barclays, GlaxoSmithKline also received a Sell from J.P. Morgan’s Zain Ebrahim in a report issued on June 9. However, on June 15, UBS maintained a Hold rating on GlaxoSmithKline (LSE: GSK).

See today’s best-performing stocks on TipRanks >>

Based on GlaxoSmithKline’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p7.63 billion and a net profit of p1.74 billion. In comparison, last year the company earned a revenue of p7.52 billion and had a net profit of p1.62 billion

Based on the recent corporate insider activity of 327 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GSK in relation to earlier this year.

Read More on GB:GSK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).